

Phase I Study: Quotient Code QSC300759

Submission date 30/10/2025	Recruitment status No longer recruiting	☒ Prospectively registered ☐ Protocol
Registration date 31/10/2025	Overall study status Deferred	☐ Statistical analysis plan ☐ Results
Last Edited 31/10/2025	Condition category Other	☐ Individual participant data ☒ Record updated in last year

Plain English summary of protocol

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)

Principal investigator

Contact name

Dr Litza McKenzie

Contact details

Quotient Sciences Limited
Mere Way
Ruddington Fields
Ruddington
Nottingham
United Kingdom
NG11 6JS
+44 (0)330 303 1000
recruitment@weneedyou.co.uk

Type(s)

Public, Scientific

Contact name

Dr Novartis Study Director

Contact details

Lichtstrasse 35
Basel
Switzerland

4056
+41 (0)61 324 11 11
novartis.email@novartis.com

Additional identifiers

Integrated Research Application System (IRAS)
1010366

Protocol serial number
Quotient code QSC300759

Study information

Scientific Title
Phase I Study: Quotient Code QSC300759 [the full scientific title will be published within 30 months after the end of the trial]

Study objectives
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required
Ethics approval required

Ethics approval(s)
Submitted 01/09/2025, London - Harrow REC (Health Research Authority, 2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 (0)2071048357; harrow.rec@hra.nhs.uk), ref: 25/LO/0485

Primary study design
Interventional

Study design
Relative bioavailability study in healthy volunteers

Study type(s)
Other

Health condition(s) or problem(s) studied
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Interventions
The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Primary outcome(s)

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Key secondary outcome(s)

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Completion date

22/02/2026

Eligibility**Key inclusion criteria**

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Participant type(s)

Healthy volunteer

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Upper age limit

55 Years

Sex

All

Key exclusion criteria

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment

05/11/2025

Date of final enrolment

22/02/2026

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Quotient Sciences Limited

Mere Way

Ruddington Fields

Ruddington

Nottingham

United Kingdom

NG11 6JS

Sponsor information

Organisation

Novartis Pharmaceuticals UK Limited

Funder(s)

Funder type

Industry

Funder Name

Novartis Pharmaceuticals UK Limited

Alternative Name(s)

Novartis UK, NOVARTIS UK LIMITED

Funding Body Type

Private sector organisation

Funding Body Subtype

For-profit companies (industry)

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

Not expected to be made available

IPD sharing plan summary

Not expected to be made available